Summary.-Tumours were induced s.c. in C3H/uip, SJL/uip, DBA/2 uip, C57BL/6 uip and BDF1 mice by different doses of methylcholanthrene (MCA) diluted in oil: 1 mg, 0.1 mg and 0.01 mg. In each mouse strain, tumour frequency showed a different decreasing pattern in relation to the decreasing dose of MCA. Tumour latent period (LP) increased between the lmg and 0-1mg doses of MCA, but the 0-01mg dose induced tumours with a similar or shorter LP than those tumours induced by 1 mg. Half of the tumours were treated with two injections of intratumoral (IT) BCG. The strains of mice differed in their sensitivity to this treatment, but only tumours induced by 0-01 mg MCA were sensitive to IT BCG. The induction of tumours by MCA pellets gave similar results. After transplantation of the untreated tumours, very few were cured by BCG treatment. Analysis of the role of tumour LP, growth rate and immunogenicity favours a slow growth rate as the most important characteristic for BCG sensitivity of the primary tumour. The tumours induced by 0-01 mg MCA were less immunogenic than those induced by 1 mg MCA, but the difference was not significant. This finding permits us to exclude an important role for tumour immunogenicity in the sensitivity of the primary tumour to BCG.
As RECENTLY CLAIMED by Baldwin (1976) , Bartlett et al. (1976) and Martin et al. (1977) the results of tumour immunotherapy assays with transplanted tumours induced by large doses of carcinogen are not easily applied to human tumours.
"Spontaneous" tumours are not frequent enough in animals to allow the study of a particular treatment in many animals over a short time. A few animal strains have a high frequency of "spontaneous" tumours, but they have been selected for this character and do not represent a natural situation.
We attempted to avoid some of these problems by testing a tumour-immunotherapy system on primary tumours induced by various doses of carcinogen in different strains of mice. The immunotherapy used, injection of BCG into the tumours, was first described for the treatment of human melanoma (Morton et al., 1970) transplanted guinea-pig tumour (Zbar & Tanaka, 1971 ) and transplanted rat tumours (Baldwin & Pimm, 1971; Chassoux & Salomon, 1975) . Indeed this mode of treatment contains two of the important conditions for successful tumour immunotherapy compiled by Bast et al. (1976) : a small tumour burden and direct contract between BCG and tumour cells. The BCG strain from the Pasteur Institute has been shown to be one of the most effective for tumour immunotherapy (Lagrange, 1978) .
Some tumour characteristics have been studied to define more precisely the conditions of successful immunotherapy. Baldwin & Pimm (1973a, b) studied the role of tumour immunogenicity in the success of BCG treatment. Their work shows that the growth of several non-immunogenic transplanted tumours is not suppressed by BCG (Baldwin & Pimm, 1973a ) but that i.v. injection of BCG may inhibit the growth of pulmonary metastases of a weakly immunogenic tumour (Baldwin & Pimm, 1973b) .
As far as we know, no systematic studies have been done on other tumour characteristics. Tokunoga et al. (1974) have shown that sensitivity to intratumoral (IT) BCG (regression plus recurrence of delay in growth) of primary tumours induced by 0 5 mg MCA was positively related to a short latent period (LP). Bartlett (1972) has also demonstrated an inverse correlation between the LP of the primary tumour and its growth rate. In the present study, the LP, growth rate and immunogenicity of primary tumours were examined in relation to the success or failure of therapy by IT BCG.
MATERIALS AND METHODS
Animals. Male and female C3H/uip, SJL/ uip, DBA/2 uip, C57BL/6 uip and BDFI mice, 2 months old, were obtained from the breeding facilities of our Institute. The pangeneic mice, 2 months old, were obtained from a random cross of mice of different strains; they were used at the 5th generation of random breeding.
Tumours.-Fibrosarcomas were induced by s.c. injection of 041 ml of olive oil containing 1 mg, 0-1 mg or 0-01 mg of MCA (Eastman Kodak). In a second experiment, this mode of induction was compared with the s.c. implantation of an MCA pellet (Prehn, 1975) containing°/ (0.2 mg), 0.50o (0-02 mg) or 0-050o (0-002 mg) MCA.
Latent period (LP). Animals were examined for tumour appearance during one year. LP was recorded when the tumour diameter was 4 mm.
Treatment of tumours.-On Day 0 (day ot MCA injection) mice were randomly designated to be treated or not treated by BCG when a tumour appeared.
When a primary tumour diameter reached 4-9 mm, the animal was given 2 IT injections of 1 mg BCG each (fresh BCG or immuno BCG of the Pasteur Institute) one week apart. The same treatment was applied to transplanted tumours (Chassoux & Salomon, 1975) .
For the C. parvumn treatment of tumours, the same schedule as for BCG was used. The only change was the dose used for each of the 2 injections: 109 (0 07 mg) of heat-inactivated C. parvum (No. 4182 strain of the Pasteur Institute, provided by R. Ducluzeau, CRNS, Jouy-en-Josas, France).
The mice were considered as cured when no tumour wvas present at least one year after the injection of MCA, after a tumour had appeared at that site. When a node was still detected at the old tumour site, a histological study was done to exclude the possibility of an active tumour centre.
Transplantation.-Untreated tumours were excised when their diameters were 10-12 mm.
At this size, the tumour mass was free of necrosis. Fragments of the tumour uwere frozen at -80°C in Hanks' medium containing 10°glycerol. These fragments w"ere rapidly thawed and transplanted to animals that had been wirhole-body irradiated with 400 rad X-rays 24 h previously. Tumours that developed were then transplanted to different, untreated animals for the study of BCG immunotherapy or oftumour immunogenicity.
Measurement of growth rate. For both primary and transplanted tumours, the growth rate was defined as the number of days necessary for the tumour to treble its diameter (4 to 12 mm). During this period the tumour growth is generally linear.
Measurement of immunogenicity. -The immunogenicity of the tumour was examined for untreated tumours induced by 1 mg or 0-01 mg MCA. Each tumour was transplanted s.c. on the abdomens (SCV) of 6-8 mice as a fragment of about 1 mm3. When the tumour diameter reached 10-12 mm, the tumour was excised. Two weeks after the excision, a fragment of the same tumour was transplanted s.c. on to the backs (SCD) of these mice.
A recurrence at the first implantation site excluded the animal from the record of takes. The take and growth rates of the second tumour grafts indicate, when compared with those of the first tumour grafts, the degree of immunization of the animals. Each tumour was classified for immunogenicity (4 to 0) from the plotted results so that the different groups could be compared. The strains in increasing order of sensitivity to MCA induction were: C57BL/6, C3H, DBA/2 and SJL. The pattern of decreasing tumour frequency among the Fl hybrids (C57BL/6 x DBA/2) was similar to that of the C57BL/6 strain, but with a higher frequency for the 2 lower doses of MCA. Latent period (LP) Tumour appearance was recorded separately for male or female mice because of significant sex differences in the LP of tumours induced by 1 mg MCA (C3H and SJL). Tables II and III show that, in general, the LP of the tumour increased between the 1mg and 01 mg doses (SJL Y, P < 0 05; C3H S, P < 0.01). The tumours induced with 0 01 mg MCA had an LP similar to or shorter than (C3H Y, P < 0-05; BDFI1, P < 0-01) those induced by 1 mg. P values were determined by the Mann-Whitney U test.
BCG treatment of the primary tumours
No cure was seen for the lmg MCAinduced tumours, and only one cure for those induced by 01 mg (Table IV) . A comparison of all tumours shows no difference of growth rate between early and late tumours: LP < 110 days:38.1 + 6-4 (37); LP >110 days:46-1+27-3 (7); P = 0-42 (Mann-Whitney U test). The 110-day cut-off for the latent period was chosen because beyond this limit 3 strains and the BDF1 mice showed a lack of tumour appearance for various periods of time.
Transplanted tumours. The immunogenicity value is calculated for each tumour after transplantation SCV to 6-8 mice, tumour excision, and retransplantation of the same tumour SCD. The comparison of takes of the first tumour graft (0-25 or 26-75 or 76-100%) with the takes of the second graft, plus the delay in the growth of this second graft (+ or -) give to each tumour a value in the classification representing the degree of immunogenicity: from 4 (high immunogenicity), down to 0 (no immunogenicity).
at least one of these 4-7 tumours had a growth rate similar to that of the primary tumour, we discount the difference.
The results are shown in Table IX . No tumour had a slower growth after transplantation, and 10/19 tumours had a faster growth.
Immunogenicity
The legend of Table X indicates the method of calculating the immunogenicity of each tumour from 4 (high immunogenicity) to 0 (no immunogenicity).
The mean immunogenicity of the lmg group was higher than that of the OOlmg group, but the difference was not significant (P = 0.088). It is noteworthy that, in the group of tumours induced with the highest dose of MCA, 7/17 had no or little immunogenicity (0-0.5). If we separately consider the tumours induced in females, we obtain: 1-7 (0-3.5) as mean immunogenicity for 10 tumours induced by 1 mg MCA and 0-61 (0-2 5) as mean immunogenicity for 9 tumours induced by 0-01 mg MCA. The difference is significant by the Mann-Whitney U test: P < 0 05. marked depression in the anti-SRBC response 7 days (P<0-01) and 14 days (P < 0 01) after the injection of MCA. By Day 79, the animals had begun to recover part of their response.
After the injection of 04 mg, the response was also rapidly depressed, but this depression was less and shorter-lived (Day 7: P < 0-01, Day 14: non-significant) than with the 1 mg dose. After the injection of 0 01 mg, we noted a depression in the anti-SRBC response that was stronger than that after the 0.1mg dose; this depression was still present at Day 79 (P < 0-01).
1)ISCUSSION
The various sensitivities of different mouse strains to tumour induction by MCA were described a considerable time ago (Chouroulinkov et al., 1961) .
The latent period (LP) of tumours induced by low doses or concentrations of carcinogen has been shown to be longer than that of tumours induced by high doses or concentrations (Slaga et al., 1974; Prehn, 1975) . This may be linked with the immunodepressive potency of the carcinogen dose (Stutman, 1975) . Indeed, after induction of tumours by a low concentration of MCA in pellet, we obtained a slight increase in the tumour LP. On the contrary, results from the use of a very low dose of MCA in oil (0-01 mg) seem to be inconsistent with this supposition, because the tumours induced with 0-01 mg MCA in oil had similar or shorter latent periods than the lmg-induced tumours.
Our study on the immunodepressive potency of the 3 doses in pangeneic mice shows a second discrepancy. The lmg dose induces a strong depression which is probably due to its toxicity towards all lymphocytes. With the 0 1mg dose, we see a slighter depression, with an earlier recovery of the immune response. But with the O0Olmg dose, the depression is at about the same level as with the 1mg dose, and continues to Day 79. There is no continuous proportionality between the dose of MCA and the level and duration of the induced immune depression. These results could partly explain the appearance of early tumours after the lower dose. A more extensive study is needed to confirm this point.
Primary tumours induced by 0-5 mg of MCA were treated with IT BCG by Tanaka (1974) and Tokunoga et al. (1974) . In Tanaka's work, 1/7 tumours grew more slowly after one injection of 2 x 107 BCG organisms. In Tokunoga's work, after one injection of 1 x 108 BCG organisms: 8/30 tumours grew more slowly, 5/30 regressed and then recurred. In these two experiments, there was no cure of tumours. No spontaneous regressions were recorded and in Tokunoga's work, only 1/19 tumours grew more slowly in the control group. This absence of cure is consistent with our results, because we obtained cures of tumours only when they were induced by 0-01 mg MCA; the tumours induced by higher doses were resistant to BCG. We have previously observed (Chassoux & Salomon, 1975; Salomon & Lynch, 1976) that transplanted mouse tumours induced by large doses of carcinogen were rarely cured by IT BCG. This was confirmed in the present experiment with transplanted tumours.
These results lead us to distinguish between the tumour growths in the primary host and in the transplanted host. In tumour groups where we observe spontaneous regressions, the primary tumour grows at the same time as spontaneous rejection mechanisms develop. It is only later that one of these antagonistic phenomena wins over the other. At this time, the BCG injected IT has its greatest effect, creating a larger number of regressions than the spontaneous rejection mechanisms alone. It is likely that spontaneous rejection mechanisms and BCGstimulated mechanisms partly overlap; macrophages and NK cells are probably more involved in the response to these weakly immunogenic tumours than are T cytotoxic lymphocytes. These cell populations are usually implicated in the thymus-independent immune surveillance (Meltzer, 1976; Wolfe et al., 1977) . After trocar transplantation, the period between the implantation of tumour cells and the palpable tumour appearance is too short to allow the same mechanisms to develop. A similar phenomenon to that observed with primary tumours would perhaps be seen if fewer cells were transplanted. However, we cannot be sure that the transplanted tumour that arises does not result from selection of the most aggressive cell or cells.
We The slower growth rate of the tumours induced by 0-01 mg MCA in oil does not seem to be linked to a long LP, as suggested by Bartlett (1972) . The mechanism of MCA action on cell transplantation by mutation leads us to suggest a proportional relationship between the number of genes affected and the dose of MCA. We assume that, among survivor cells, the largest doses of MCA induce more mutations and give a more heterogeneous population of transformed cells; the clones which are best equipped for growth rate, invasiveness and immune depression of the host are more likely at the origin of the resultant tumours. By contrast, the tumours induced by low doses may be more homogeneous and of low malignancy, characteristics that would be involved in the spontaneous regressions.
For 9/19 tumours, growth rate was unchanged after transplantation, whereas the other 10/19 tumours showed an accelerated rate (although we partly avoided immune selection by whole-body irradiation of the animals before the tumour graft). An increase in growth rate after transplantation of primary tumours has already been observed by Foley (1953) . The fact that BCG acts particularly on primary tumours which have a low growth rate could explain the frequent failure of BCG therapy on transplanted tumours with an accelerated growth rate.
Tumour immunogenicity was considered by Baldwin & Pimm (1973a) to be involved in the success of BCG therapy. Two of their experimental conditions differ from ours: 1, they used transplanted tumours instead of primary tumours, and 2, they made suppression whereas we made regression experiments. It is very likely that host-tumour relationships are not the same in a system where the tumours start from transformed cells and develop through a selection procedure in the organism and in systems where a large number of relatively homogeneous tumour cells from a stabilized transplanted tumour are injected in one shot into a healthy animal.
In our preliminary results, although we obtain a lower mean immunogenicity for tumours induced by 0-01 mg MCA in oil than for the tumours induced by 1 mg MCA in oil, the difference is not statistically significant. This lack of significance is probably due to the dispersion ofthe values brought about by the presence of nonimmunogenic tumours among those induced by 1 mg MCA. The appearance of a large number of non-immunogenic tumours has been observed by Bartlett (1972) . In a comparison of early tumours induced by 3 different concentrations of MCA, Prehn (1975) also obtained a marginal difference between the immunogenicity of groups induced by a high concentration and those induced by a low concentration of MCA. This tendency towards a reduction of immunogenicity with decreasing dose of MCA leads us to exclude an important role for a high immunogenicity in the mechanisms of BCG action on primary tumours.
The mechanism of BCG action in this system is not known, but nonspecific reactions must be involved. Lynch & Salomon (1977) have shown that the injection of BCG into the tumour provokes the penetration of blood components, humoral and cellular, into the tumour circulation, where they did not have access before. At the time of this reaction, 4 types of cells can be involved in the cellular anti-tumour reaction of the host: T cells and cells acting in antibodydependent cellular cytotoxicity which involve specific anti-tumour immunity, cytotoxic macrophages, and NK cells which involve nonspecific immune rejection. We do not know which cell type or antibody plays a role in the observed tumour regression, as BCG can stimulate all these potential effectors. In the case of transplanted tumours, we have shown (Salomon & Lynch, 1976) that, depending on the tumour, cure after IT BCG sometimes produces specific anti-tumour immunity. In the present experiment with primary tumours we did not challenge the cured mice with the tumour; thus we cannot know whether these mice were specifically immune towards it.
The results reported here show the importance of the use of primary tumours induced by low doses of carcinogen for testing tumour immunotherapy systems. The transplantation of the tumour frequently modifies at least one of the primary tumour characteristics which is necessary to BCG action. The tumours sensitive to BCG, in general, are induced by a low dose of MCA (0-01 mg); their characteristics are a slow growth rate and a tendency towards a low immunogenicity, which are both probably related to a low malignancy, as some of them regress spontaneously.
Primary tumours induced by low doses of carcinogen having a low or high rate of disappearance in the host have to be studied for their short or long latent period, their slow or rapid growth rate and their low or high immunogenicity, with the aim of controlling the immunotherapy and of achieving a better transfer of experimental observations to conditions in humans.
